uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Surfactant replacement therapy in preterm infants: a European survey
Department of Neonatology, Emma Children’s Hospital, Academic Medical Center, Amsterdam, The Netherlands.
Department of Neonatology, Emma Children’s Hospital, Academic Medical Center, Amsterdam, The Netherlands.
Department of Neonatology, Emma Children’s Hospital, Academic Medical Center, Amsterdam, The Netherlands.
Pediatric and Neonatal Intensive Care, Department of Pediatrics, University Hospital of Geneva, Geneva, Switzerland.
Show others and affiliations
2011 (English)In: Neonatology, ISSN 1661-7800, E-ISSN 1661-7819, Vol. 100, no 1, 71-77 p.Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Exogenous surfactant is an undisputed treatment for neonatal respiratory distress syndrome but its efficacy is highly dependent on the treatment strategy. International guidelines have published recommendations on the optimal surfactant replacement strategy.

OBJECTIVE: To determine how evidence-based guidelines on surfactant replacement therapy are implemented in daily clinical practice.

METHODS: Data on surfactant replacement therapy, including preparation, dosing and timing, were collected in 173 European neonatal intensive care units (NICUs) by questionnaire and in a cohort of preterm infants mechanically ventilated on two separate predefined dates in these units.

RESULTS: All NICUs used animal-derived surfactant in the treatment of respiratory distress syndrome, with Poractant being most widely used (86%). The most frequently used first dose was 100 mg/kg (58%) and 200 mg/kg (39%) and all NICUs allowed for repeat dosing. 39% of the NICUs claimed to use prophylactic treatment (<15 min of life). Data on surfactant treatment were collected in 338 infants, with a median gestational age of 27 weeks and a birth weight of 860 g. All infants were treated with animal-derived surfactant. The median first dose was 168 mg/kg in the Poractant group compared with 100 mg/kg in the Beractant and Bovactant groups. Prophylactic treatment was used in 23% of the infants and 28% of the infants received surfactant >2 h after birth. 43% of the infants received multiple doses.

CONCLUSIONS: With the exception of surfactant timing, guidelines on surfactant replacement therapy seem to be implemented in daily clinical practice in European NICUs.

Place, publisher, year, edition, pages
2011. Vol. 100, no 1, 71-77 p.
National Category
Pediatrics
Identifiers
URN: urn:nbn:se:uu:diva-163089DOI: 10.1159/000322004ISI: 000291160900013PubMedID: 21228602OAI: oai:DiVA.org:uu-163089DiVA: diva2:462691
Note

Co-author: Richard Sindelar, Uppsala universitet, Institutionen för kvinnors och barns hälsa, forskargrupp Perinatal, neonatal och barnkardiologisk forskning/Hellström-Westas, ingår i "the Neovent Study Group" och nämns i slutet av publikationen.

Available from: 2011-12-07 Created: 2011-12-07 Last updated: 2017-12-08Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Authority records BETA

Sindelar, Richard

Search in DiVA

By author/editor
Sindelar, Richard
By organisation
Pediatrics
In the same journal
Neonatology
Pediatrics

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 407 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf